Sky Century Investment Valuation
Is SKYI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SKYI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SKYI ($0) is trading below our estimate of fair value ($0.21)
Significantly Below Fair Value: SKYI is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SKYI?
Key metric: As SKYI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SKYI's PS Ratio? | |
|---|---|
| PS Ratio | 3.2x |
| Sales | US$74.76k |
| Market Cap | US$750.17k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.2x |
| Enterprise Value/EBITDA | -7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SKYI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.3x | ||
BIMI BIMI Holdings | 0.008x | n/a | US$104.7k |
FZMD Fuse Medical | 0.3x | n/a | US$5.8m |
PDRX PD-Rx Pharmaceuticals | 0.3x | n/a | US$5.9m |
ATPC Agape ATP | 4.6x | n/a | US$6.2m |
SKYI Sky Century Investment | 3.2x | n/a | US$750.2k |
Price-To-Sales vs Peers: SKYI is expensive based on its Price-To-Sales Ratio (3.2x) compared to the peer average (1.3x).
Price to Sales Ratio vs Industry
How does SKYI's PS Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: SKYI is expensive based on its Price-To-Sales Ratio (3.2x) compared to the US Healthcare industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is SKYI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate SKYI's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Elevance Health
US$93.2b
Operates as a health benefits company in the United States.
ELV
US$402.75
7D
1.3%
1Y
-13.5%
Centene
US$30.3b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$59.93
7D
1.4%
1Y
-15.0%
Sensus Healthcare
US$141.1m
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
SRTS
US$8.60
7D
-3.8%
1Y
252.5%